Product Image

Contributor Information

  • Name Anne-Marie Mes-Masson and Diane Provencher
  • Institute Centre Hospitalier de L’université de Montréal
  • Primary citation Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941

Tool Details

  • Tool name: OV-866 (2) cell line
  • Alternate names: OV-866 (2)
  • Tool type: Cell Lines
  • Organism: Human
  • Donor: Age of diagnosis:60; BRCCA hereditary status: negative; Grade 2 – Stage IIIC; Mutations: TP53; Carboplatin/Taxol
  • Tissue: Derived from ascites
  • Gender: Female
  • Cancer type: Gynaecologic cancer
  • Morphology: Predominantly small epithelial type cells, often aggregated, and fibroblast shaped cells notably absent. Formed loose compat spheroids with irregular margins
  • Growth properties: Adherent
  • CRISPR: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serous ascites of patients with recurring disease and who had been treated with chemotherapy prior to collection. The '2' after OV866(2) refers to the fact that this cell line was established from a second ascites sample from the patient
  • Research area: Cancer
  • Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
  • Additional notes: Taken from female who was age 60 at diagnosis, BRCA hereditary was negative, disease stage was IIIC. No prioir personal history of cancer or prioir oncologic treatment, and was not chemotherapy naive at the time of sample collection

  • For Research Use Only

Target Details

Application Details

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics?: Amphotericin B and Gentamicin

Documentation

Related Tools

Product Image

HDL2 iPSCs cell line

#156417
Product Image

Human Melanocyte [bFGF] Cell Line

#154111
Product Image

U-251/EGFP_LC3

#161142

References

  • •  Vias et al. 2023. Elife. 11
  • •  12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
  • •  14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
  • •  15(9):2566. PMID: 37174032